

VX-809 (Lumacaftor)

VX-809 (Lumacaftor) is an experimental drug for the treatment of cystic fibrosis in development by Vertex Pharmaceuticals. VX-809 is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanine in position 508 is missing, is found in about 60% of cystic fibrosis patients in Europe, and in about 90% of persons with some mutation in the CFTR gene.

Materials Provided

Catalog Number:	92-1248
Quantity Supplied:	1 vial(s), 5 mg per vial

Description

DiscoverX control ligands have been functionally tested and validated for optimal use with all cell line targets and Assay Ready kits.

Product Information

Molecular Weight:	452.41 g/mol
Source:	Synthetic
Purity:	≥ 99%
Endotoxin Level:	N/A
Formulation:	N/A
Storage:	-20°C Please avoid multiple freeze/thaw cycles.

Reagent Preparation

To avoid condensation, equilibrate the vial to ambient temperature before opening.

Stock Concentration:	50 mM
Reconstitution Volume:	0.221 mL
Reconstitution Solvent:	DMSO

For Research Use Only

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com
Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com
General product information: www.discoverx.com